EMCURE Emcure Pharmaceuticals Q4 FY26 results (Jan–Mar 2026) and concall
Emcure Pharma delivered a strong FY26, exceeding revenue guidance with 16.6% growth to ₹9,204 crores and over 40% adjusted PAT growth. International markets were a key driver, while domestic growth in Q4 was softer due to Zuventus restructuring, which management expects to recover. The company outlined strategic partnerships, pipeline advancements, and provided positive guidance for FY27 revenue and EBITDA margin expansion, despite acknowledging potential geopolitical cost pressures.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 16.7%, net profit up 23.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 2,002 | 1,963 | 2,116 | 2,101 | 2,270 +13% | 2,363 +20% | 2,470 +17% |
| EBITDA | 381 | 355 | 402 | 417 | 475 +25% | 493 +39% | 480 +19% |
| Net profit | 202 | 156 | 197 | 215 | 251 +24% | 231 +48% | 244 +24% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
